SNT-20109 / Sonata Therap - LARVOL DELTA

Sonata Therapeutics Presents Data Supporting its Network Medicines Approach at SITC 2023 (Businesswire) - "Sonata Therapeutics, Inc...will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The posters highlight Sonata’s proprietary Intrinsic Antigen Release Technology (iART) and two of the company’s oncology programs, all of which demonstrated in vivo efficacy in a variety of tumor models...Key takeaways...Delivered intratumorally, SNT-3010912 induced a state-of-the-art form of enhanced immunogenic antigen release...Mice treated with SNT-20109 showed significant tumor growth inhibition, and nine of the ten subjects showed complete regression, indicating it could drive a unique immunological cascade with broad potential for future cancer treatment investigations....SNT-101 potently reduced viability, and induced cell death and lipid peroxidation in both cell lines, resulting in significant target exposure and tumor growth inhibition."

Preclinical • Oncology • Solid Tumor

SNT-20109 induces protective immunity in the murine syngeneic tumor cell line, CT26: a dual approach of direct cytotoxicity and defined immune activation (SITC 2023) - "Conclusions SNT-20109 induces an innovative form of enhanced-ICD that has never before been characterized. The therapeutic potential of this approach presents an exciting avenue for future cancer treatment investigations."

Preclinical • Tumor cell • Hematological Malignancies • Oncology • Solid Tumor

Sonata Therapeutics Announces Presentations Supporting its Network Medicines Approach at SITC 2023 (Businesswire) - "Sonata Therapeutics, Inc...announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting....One of the poster presentations will highlight one of Sonata’s Network Medicines, iART, that reprograms diseased cells to become the coordinators of cure for various indications including cancer....The second poster presentation will highlight how SNT-20109, one of Sonata’s lead oncology programs, can induce protective immunity and an innovative form of enhanced-immunogenic cell death that has never been characterized in murine cancer models. The third poster presentation will highlight SNT-4288, another of Sonata’s lead oncology programs, as a novel tool to induce ferroptosis for the treatment of sarcoma."

Preclinical • Oncology • Sarcoma • Solid Tumor